ACB Stock Analysis & Forecast (2026)

Aurora Cannabis Inc. Healthcare Drug Manufacturers - Specialty & Generic
$3.70
Current Price
55%
Hold
View Plans
Data refreshed: April 22, 2026

Key Financial Metrics

Market Cap
$218.77M
Revenue Growth
6.8%
Gross Margin
36.0%
Net Margin
-22.5%
Return on Equity
-15.5%
Debt/Equity
0.18

AI Analysis Summary

Aurora Cannabis Inc. (ACB) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry with a 55% Hold Score. Key strengths include Gross Margin (36.0%), Debt/Equity (0.18). Areas to watch: Net Margin (-22.5%), Return on Equity (-15.5%). Our AI evaluates 8 fundamental categories including revenue growth, margin quality, balance sheet strength, cash flow generation, return on capital, and valuation metrics.

Revenue Growth: Moderate Gross Margin: Good Net Margin: Negative Return on Equity: Negative Debt/Equity: Low Risk

This analysis is generated by StrongBuyAnalytics AI using publicly available financial data from SEC filings, earnings reports, and market feeds. It is not personalized investment advice. See our methodology and disclaimer.

ACB Fundamental Analysis Report
PDF Report Preview
55%
Strong Buy Score
  • 8 Fundamental Categories Analyzed
  • Revenue & Growth Trends
  • Margin & Profitability Analysis
  • Balance Sheet Strength
  • Cash Flow Quality
  • Valuation Assessment
  • AI-Powered Investment Insights
Get Your Free ACB Report

How It Works: AI Stock Analysis in 60 Seconds

See how our AI analyzes ACB fundamentals to generate buy/sell signals and Strong Buy Scores.

Why ACB Has a 55% Score

Our AI evaluates Aurora Cannabis Inc.'s fundamentals across multiple dimensions. Here is what is driving the current Hold rating:

Recent Catalysts for ACB

Key developments and data points that may impact Aurora Cannabis Inc.'s trajectory:

Earnings declined -94.7% — watch for stabilization in coming quarters.
Wall Street consensus target is $6.39 (+72.8% from current price), based on 1 analyst estimates.
Analyst consensus recommendation: Buy.
Short ratio of 12.4 days to cover — elevated short interest could fuel a squeeze on positive news.

ACB vs. Peers

How Aurora Cannabis Inc. stacks up against comparable Healthcare companies on key metrics:

Ticker Price Market Cap P/E Rev Growth Net Margin ROE
ACB $3.70 $218.77M 6.8% -22.5% -15.5%
JNJ $227.02 $547.10B 20.6x 9.9% 21.8%
UNH $353.72 $321.06B 26.8x 12.3% 2.7% 12.5%
PFE $27.27 $155.15B 20.1x -1.2% 12.4% 8.9%
MRK $112.73 $278.71B 15.5x 5.0% 28.1% 36.9%

Main Risks for ACB Investors

Every investment carries risk. Here are the specific risk factors our analysis identified for Aurora Cannabis Inc.:

Net Margin (-22.5%)
Return on Equity (-15.5%)
High beta of 1.32 means the stock is 32% more volatile than the market — expect larger drawdowns in corrections.
Short interest is elevated with a 12.4-day cover ratio, indicating bearish bets against the stock.

Generate the full PDF report for a detailed risk-reward framework and bear-case scenarios.

ACB Balance Sheet & Cash Flow

A snapshot of Aurora Cannabis Inc.'s financial health based on the most recent filings:

Total Cash
$108.45M
Total Debt
$101.00M
Current Ratio
3.06
FCF Yield
5.4%
EBITDA
$-32,735,000
Operating Margin
2.3%

Data sourced from the latest SEC filings. Generate the full PDF report for detailed balance sheet and cash flow commentary.

ACB Valuation Snapshot

Price / Book
0.5x
Below asset value
Analyst Target (Mean)
$6.39
Range: $6 – $6
52-Week Price Range — ACB is trading at 18% of its range
$3.07 (52W Low) $6.67 (52W High)

Is ACB a Buy Right Now?

Based on our AI-powered fundamental analysis, ACB has a Strong Buy Score of 55%, earning a "Hold" rating. This score synthesizes 8 key financial metrics to provide an objective investment signal.

Moderate Buy Signal

Aurora Cannabis Inc. shows mixed fundamentals with some strengths and areas to monitor. Positives include Gross Margin (36.0%). Watch for Net Margin (-22.5%).

ACB AI Buy & Sell Signals Explained

Our AI analyzes Aurora Cannabis Inc.'s financial statements to generate buy/sell signals based on quantitative metrics, not market sentiment or news headlines. Here's what drives the 55% score:

  • Revenue Growth: 6.8% year-over-year (positive)
  • Gross Margin: 36.0% (healthy)
  • Net Margin: -22.5% (unprofitable)
  • Return on Equity: -15.5% (negative returns)

Generate the full PDF report for complete category-by-category scoring and AI-powered investment recommendations.

Key Support / Demand Zones

Technical traders can view real-time demand and supply zones for ACB on our Demand Zones page. These zones identify key price levels where institutional buying or selling has historically occurred.

With ACB currently trading at $3.70, our system monitors proximity to these critical levels and can alert you when the stock approaches support or resistance zones.

Subscribe to demand zone alerts to receive real-time notifications when ACB reaches key technical levels.

Earnings & Revenue Outlook

Aurora Cannabis Inc. operates in the Healthcare sector, specifically in Drug Manufacturers - Specialty & Generic. Understanding earnings trends is crucial for forecasting ACB's trajectory.

Current revenue growth of 6.8% exceeds the average company.

Visit our Earnings Calendar to track upcoming ACB earnings dates and historical beat/miss patterns. Sign up for earnings alerts to get notified before announcements.

ACB Stock Forecast (Next 3–12 Months)

Our AI projects ACB's trajectory based on current fundamentals and historical patterns. With a 55% Strong Buy Score, here's what the data suggests:

Mixed Outlook: Aurora Cannabis Inc. shows moderate fundamental strength. Revenue growth at 6.8% is positive but warrants monitoring. The stock may trade sideways or experience modest gains depending on execution and market conditions.

For a complete 12-month price forecast with specific bull/bear scenarios, generate the full PDF report.

Valuation Metrics (P/E, Growth, Margins)

Understanding valuation is critical for determining if ACB is fairly priced. Here's the current snapshot:

  • Market Capitalization: $218.77M
  • Debt/Equity: 0.18 (conservative balance sheet)

Our AI weighs these metrics against growth rates and margin quality to determine if ACB offers compelling risk-adjusted returns at current prices.

Bull Case for ACB

Here's why investors are bullish on Aurora Cannabis Inc.:

  • Gross Margin (36.0%)
  • Debt/Equity (0.18)

While these positives exist, investors should weigh them against the risks outlined in the bear case below.

Bear Case & Risks for ACB

Every investment carries risk. Here are potential concerns for ACB investors:

  • Net Margin (-22.5%)
  • Return on Equity (-15.5%)

The full PDF report includes a detailed bear case analysis with specific risk ratings for each category.

Summary / 12-Month Outlook

ACB Summary: Aurora Cannabis Inc. earns a 55% Hold Score based on AI analysis of fundamental data. Trading at $3.70 with a $218.77M market cap, the stock presents a balanced risk/reward profile for the coming year.

Bull Case: Gross Margin (36.0%), Debt/Equity (0.18)

Watch: Net Margin (-22.5%), Return on Equity (-15.5%)

For the complete analysis with specific price considerations, growth projections, and AI-powered buy/hold/sell recommendations, generate your free ACB PDF report.

Learn More About Stock Analysis

Deepen your understanding of the concepts used in this ACB analysis:

Fundamental Analysis Guide

Learn how to evaluate stocks using financial statements and key metrics.

Understanding P/E Ratio

What P/E ratio tells you about a stock's valuation and growth expectations.

Return on Equity (ROE)

Why ROE matters for stock selection and how to interpret it.

Stock Valuation Methods

Compare DCF, P/E, and other approaches to value stocks like ACB.

What Are Demand Zones?

Find key support and resistance levels for ACB and other stocks.

How to Read Earnings Reports

Understand earnings per share, revenue surprises, and guidance.

Related Tools for ACB

Demand Zone Analyzer ACB Live Chart ACB SEC Filing News Earnings Calendar Institutional Ownership Sector Scanner Average Down Calculator

ACB SEC Filing News

Latest SEC filings for ACB explained in plain English — insider buys/sells (Form 4), proposed sales (Form 144), material events (8-K), and quarterly & annual reports.

Loading recent SEC filings…
View all ACB SEC Filing News →

Frequently Asked Questions about ACB

Is ACB a good buy right now?
ACB currently has a Strong Buy Score of 55% (Hold). ACB shows moderate buy signals. The stock has mixed fundamentals worth reviewing in detail. Generate a free PDF report for specific buy/hold/sell recommendations.
What is the ACB stock forecast for 2026?
Our AI forecasts ACB based on current fundamentals: revenue growth of 6.8%, net margin of -22.5%. The 55% Strong Buy Score reflects our outlook combining growth trajectory, margin quality, and valuation. See the full 12-month projection in your PDF report.
What are key support and resistance levels for ACB?
View real-time ACB demand zones (support) and supply zones (resistance) on our Demand Zones page. With ACB currently at $3.70, you can see how close the stock is to key technical levels. Subscribe to get alerts when ACB approaches these zones.
How do ACB fundamentals compare to peers?
Aurora Cannabis Inc. operates in the Healthcare sector. Key metrics for peer comparison: Gross margin 36.0%, ROE -15.5%, Debt/Equity 0.18. The 55% Strong Buy Score factors in how these metrics stack up against industry averages. Data is refreshed daily.
Is the ACB analysis PDF report free?
Yes! Your first ACB fundamental analysis report is completely free with no credit card required. The PDF includes the full Strong Buy Score breakdown, all 8 fundamental categories analyzed, AI-powered insights, and specific investment recommendations. Additional reports are available through our subscription plans starting at $24/month.
What is Aurora Cannabis Inc.'s market cap and P/E ratio?
Aurora Cannabis Inc. (ACB) has a market cap of $218.77M. These valuation metrics are key factors in our Strong Buy Score calculation. See all metrics in the PDF report for comprehensive valuation analysis.

This ACB analysis is for educational and informational purposes only and does not constitute financial advice. All data is sourced from public filings and market feeds. Past performance does not guarantee future results. Read our full disclaimer.